Teicoplanin A2-4
(Synonyms: 替考拉宁A2-4) 目录号 : GC14637A glycopeptide antibiotic
Cas No.:91032-37-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Teicoplanin A2-4 is a major component of the teicoplanin complex [1-3].
Teicoplanins, lipoglycopeptide antibiotics, are glycopeptide antibiotics mainly produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro. Teicoplanins consist of five major components (A2-1, A2-2, A2-3, A2-4 and A2-5), one hydrolysis component (A3-1), and four minor components (RS-1, RS-2, RS-3, RS-4) [1]. Teicoplanins have been recently used for the treatment of multitudinous aerobic and anaerobic Gram-positive infections. Teicoplanins have been rapidly and extensively absorbed from the peritoneal cavity and muscle, but very poorly absorbed from the gastrointestinal tract [2]. Teicoplanin is highly bound in plasma to albumin and in tissues. Both renal and nonrenal mechanisms have been implicated in the elimination of the drug. For at least after one day administration, the concentrations of teicoplanin in serum and urine exceeded the MIC ranging from 0.02-2 μg/ml on many pathogenic organisms [3].
References:
[1] Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans[J]. Antimicrobial agents and chemotherapy, 1992, 36(8): 1744-1749.
[2] Rowland M. Clinical pharmacokinetics of teicoplanin[J]. Clinical pharmacokinetics, 1990, 18(3): 184-209.
[3] Traina G L, Bonati M. Pharmacokinetics of teicoplanin in man after intravenous administration[J]. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12(2): 119-128.
Cas No. | 91032-37-0 | SDF | |
别名 | 替考拉宁A2-4 | ||
化学名 | 34-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-56-O-[2-deoxy-2-[(8-methyl-1-oxodecyl)amino]-β-D-glucopyranosyl]-42-O-α-D-mannopyranosyl-ristomycin A aglycone | ||
Canonical SMILES | CCC(CCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H | ||
分子式 | C89H99Cl2N9O33 | 分子量 | 1893.7 |
溶解度 | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.5281 mL | 2.6403 mL | 5.2807 mL |
5 mM | 0.1056 mL | 0.5281 mL | 1.0561 mL |
10 mM | 0.0528 mL | 0.264 mL | 0.5281 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。